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Locally advanced spiroadeno-carcinoma in the regional axillaof a breast cancer patient: hallmarks of definitive diagno-sis and management
Alicia A. Gingrich,1 Maxwell A. Fung,2Thomas Konia,2 Robert J. Canter11Division of Surgical Oncology,2Departments of Dermatology andPathology, UC Davis School of Medicine,Sacramento, CA, USA 
Abstract
Eccrine spiroadenocarcinoma is an
extremely rare malignant eccrine gland tumor
which may masquerade as other more com-
mon malignancies such as poorly differentiat-
ed squamous carcinoma or metastatic breast
cancer. We report a case of an ulcerated axil-
lary skin lesion with bulky adenopathy in a 77
year-old female with a prior history of ipsilater-
al triple negative breast carcinoma. The clear
transition of benign spiradenoma to malignant
carcinoma was essential to establishing a
definitive diagnosis and treatment plan.
Introduction
Eccrine spiradenoma, or simply spiradeno-
ma, is a relatively common benign tumor aris-
ing from the lobular portion of the cutaneous
apocrine or eccrine sweat gland, most often
seen in young adults. Spiradenoma tends to
present as small, slow-growing, painful, nodu-
lar cutaneous masses on the trunk, extremi-
ties, head and neck and are usually no more
than 1-2 cm in size.1 The dominant treatment
approach is typically surgical excision for both
diagnostic and therapeutic purposes, although
many patients elect not to seek treatment.1
Malignant degeneration of spiradenoma, so-
called malignant spiradenoma (MS) or
spiroadenocarcinoma, is an extremely rare
cutaneous adnexal tumor. Although data are
limited, the available literature indicates that
MS nearly uniformly arises from a benign pre-
existing spiradenoma.2-4 Typically, MS presents
as a previously undiagnosed lesion on the
trunk or extremities that rapidly enlarges,
changes color, ulcerates or becomes painful
and tender.2 The time period for transforma-
tion to malignancy has been reported to range
from 2 months to 75 years, although overall the
mean duration between appearance of a lesion
and malignant transformation has been esti-
mated to be 20 years.5,6
Here we report a case of an ulcerated MS
presenting with bulky adenopathy in the axilla
ipsilateral to a metachronous diagnosis of
triple negative breast carcinoma. Our case is
unique in that we show MS developing over
four months in an area anatomically adjacent
to a previous cancer, with initial concern for
recurrent metastatic breast carcinoma. The
clear admixture of benign spiradenoma and
adenocarcinoma was essential to establishing
a definitive diagnosis and treatment plan for
this patient.
Case Report
The patient is 77 year old female who was
diagnosed with metachronous ipsilateral triple
negative breast carcinoma. The surgical man-
agement of her prior breast cancer included
total mastectomy, sentinel lymph node biopsy,
and implant reconstruction. She then received
adjuvant chemotherapy before beginning a
program of cancer surveillance. The patient
was then disease free for 14 years with no evi-
dence of recurrent malignancy. 
She was in her usual state of health until 4
months prior to presentation when she noted a
palpable cutaneous mass in her axilla. The
mass was protuberant from her skin and devel-
oped ulceration. This was concerning for neo-
plasm, and hence a shave biopsy was per-
formed. Initial biopsy revealed poorly differen-
tiated carcinoma with differential diagnosis
including squamous carcinoma and metastatic
breast carcinoma. Given the clinical impres-
sion of squamous carcinoma, the patient was
referred to dermatology for wide local excision
and possible Mohs procedure. Excisional biop-
sy was then performed. Although a complete
excision was not achieved, pathologic evalua-
tion established a diagnosis of spiroadenocar-
cinoma based on a clear association of a
benign spiradenoma precursor lesion with sur-
rounding malignant degeneration.
As shown in Figure 1, histologic evaluation
of the specimen was consistent with spirade-
nocarcinoma with lesional tissue extending to
the borders of excision. Microscopically, the
excision yielded poorly differentiated spirade-
nocarcinoma associated with an underlying
nodule of spiradenoma as well as a tumor nod-
ule containing mixed spiradenoma and spi-
radenocarcinoma. Nuclear P53 staining was
present in the malignant portion of the neo-
plasm and variable staining in the transition
from benign-appearing spiradenoma to a
malignant morphology. Staining for smooth
muscle actin highlighted surrounding myoep-
ithelial cells in the spiradenoma, while loss of
expression surrounding the malignant portion.
Estrogen and progesterone receptor staining
was negative, but interestingly (and distinct
from the patient’s prior breast carcinoma),
staining for HER2/Neu was 3+ by immunohis-
tochemistry. The carcinoma was considered
poorly differentiated because it was composed
of sheets of pleomorphic cells, mitotically
active, and had associated areas of necrosis.
Areas of vascular space invasion were also
noted.
The patient was then referred to surgical
oncology for definitive surgical management.
Given the possibility that the tumor represent-
ed a delayed regional recurrence of her origi-
nal breast carcinoma, pathologic review of her
original mastectomy specimen was performed.
This revealed an invasive ductal carcinoma
with a modified Bloom Richardson grade of 3.
Pathologic review also confirmed tumor-free
surgical margins in the mastectomy specimen,
and there was no evidence of skin involvement
by the primary breast cancer. Similarly, there
were no features of sebaceous gland differen-
tiation. Taken together, the findings were con-
sistent with the conclusion that these were
morphologically distinct tumors.  
Surgical oncology evaluation revealed an
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open granulating wound in the posterior axil-
lary fold adjacent to the proximal aspect of the
right upper extremity. There was no clinical
evidence of residual tumor. PET/CT was per-
formed to evaluate her extent of disease
(Figure 2). This revealed significant FDG avid
hypermetabolic activity in the ipsilateral axilla
consistent with regional metastasis. There
was no evidence of distant metastatic disease.
Given the absence of distant disease, the deci-
sion was made to proceed with re-excision of
the surgical site and axillary node dissection.
At the time of surgery, the open wound with
scar formation was identified in the posterior
right axilla, and an elliptical incision was
removed to include a 1-2 cm margin around
the lesion. Given the concern for regional
metastasis, a sentinel lymph node biopsy was
completed to stage the regional axilla.
Metastatic carcinoma was confirmed in frozen
section, and therefore a complete axillary
lymph node dissection was performed. The
skin defect was repaired with a skin graft.
Nine of thirty lymph nodes were positive
for poorly differentiated spiradenocarcinoma
with evidence for extracapsular extension.
Following an uneventful postoperative recov-
ery with excellent skin graft take, the patient
was referred for adjuvant radiotherapy based
on epidemiological data showing improved
oncologic outcome following adjuvant radio-
therapy.7
Discussion
In 1956, Kersting and Helwig first described
eccrine spiradenoma as a skin adnexal neo-
plasm with a slow growth pattern.8 The first
reported case of malignant transformation to
MS was described by Dabska in 1972.9
Fortunately, this transformation is rare as
malignant sweat gland tumors are estimated to
account for only 0.005% of all skin tumors.10
A definitive diagnosis of MS requires
histopathological examination. A malignant
adnexal neoplasm is arranged in ragged
sheets, solid masses with central necrosis,
nests, cords, and occasional irregular glandu-
lar structures with loss of periodic acid-Schiff-
positive basement membrane.2 Malignancy is
further assessed by findings of increased
mitotic rate, nuclear atypia, pleomorphism,
hyperchromasia, infiltrative border, hemor-
rhage, and absence of the characteristic two-
cell population.11,12 Most high-grade tumors
also display areas of focal abnormal squamous
or sarcomatous differentiation.
Immunohistochemically, these tumors dis-
play a variety of cytokeratins and antigens.
There are also reports of estrogen receptor
expression in MS, which may increase diag-
nostic overlap with other malignancies.12
Overexpression of p53 is attributed to malig-
nant transformation, as was observed in our
specimen following surgical excision.3,5
By definition, MS requires finding a focus of
benign spiradenoma within or adjacent to the
malignant tumor.2,3,12 Without an identifiable
benign focus, the lesion may be confused with
other skin cancers or metastatic disease, as
was a concern in our patient. Proper identifi-
cation of the tumor is paramount, as the man-
agement of sweat gland tumors may differ
sharply from other similarly presenting neo-
plasms on the trunk and extremities. While MS
typically arises from de novo eccrine spirade-
noma, two case reports have documented MS
arising over the course of years in an area of
previous trauma.11,13 Additionally, there have
been two case reports of rare de novo develop-
ment of MS, not preceded by spiradenoma or
trauma. These cases were noted to arise on the
forehead and nose, respectively, and the latter
was diagnosed synchronous with metastatic
colon cancer.14,15 One previous case of eccrine
carcinoma presenting as an ulcerated mass in
the breast of a male patient has also been
reported.16 Although there exists one published
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Figure 1. Histologic features of spiradenocarcinoma arising in association with spirade-
noma. A) Pure spiroadenoma is characterized by circumscribed nodules composed of
slender interanastamosing strands of basaloid epithelial cells with occasional duct forma-
tion. B) Pure spiradenocarcinoma composed of solid nodules of atypical basaloid cells. C)
Focal connection of spiradenocarcinoma to the epidermis supports a primary cutaneous
carcinoma rather than metastatic carcinoma. D) One tumor nodule contained mixed spi-
radenoma and spiradenocarcinoma. The more basaloid component represents spiradeno-
ma (10×, Hematoxylin & Eosin).
Figure 2. Findings on cross-sectional imaging showing bulky adenopathy in the right
axilla (A, white arrows) which is highly FDG avid (B).
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case report of scalp eccrine carcinoma occur-
ring in a patient with a prior history of radio-
therapy for cervical cancer,17 there are no
known cases linking prior radiotherapy to the
development of a secondary spiroadenocarci-
noma.
Definitive classification of this tumor from
other malignancies is crucial in guiding the
multimodality treatment recommendations
and care for the patient.  In verified MS, the
mainstay of therapy is surgical excision with
1-3 cm clinical margins that are histologically
confirmed as microscopically uninvolved. In
the absence of metastatic disease, this
approach is considered curative in nature.2,11
The limited outcomes data for MS suggest that
recurrence is most likely to occur within the
first 12-36 months following diagnosis and
treatment of the index neoplasm.12 Regional
lymph nodes should be dissected if tumor
metastases are diagnosed.2,7 As was the case in
our patient, surgical resection, including axil-
lary lymph node dissection, was indicated in
the setting of locally advanced disease includ-
ing regional metastases.7 Had this lesion
proved to be recurrent metastatic disease from
her history of breast carcinoma, multimodality
treatments would have included further sys-
temic chemotherapy given the natural history
and disease biology of triple negative breast
carcinoma. In contrast, there are no data to
support the use of adjuvant chemotherapy for
malignant adnexal tumors, and the risks of
chemotherapy were felt to outweigh the bene-
fits. Overall, disease-specific survival of MS
tends to be poor when compared to other
malignant cutaneous adnexal tumors. A popu-
lation-based study revealed the mortality rate
of MS to be 21%, which is comparable to a past
literature review citing 18%.7,18 While the over-
all metastatic rate for malignant cutaneous
tumors is estimated at approximately 13%,
there are few, if any, data to determine the
metastatic rate for MS.12 The occurrence of
metastases has been as high as 39% in one
study and as low as 8% in another.6,12 When MS
does metastasize, the dominant sites of failure
include the regional lymph nodes, lungs, brain,
and liver.2,7 Local control is crucial, as metas-
tases are rarely reported without preceding
local recurrence.6
There are limited data regarding the role of
adjuvant chemotherapy and radiation in this
extremely rare neoplasm. Chemotherapy in
these patients requires further study, with very
little evidence available in such a small patient
population to support a specific regimen.3
Tamoxifen therapy has been successfully used
in a patient whose cancer was estrogen recep-
tor positive with no evidence of disease recur-
rence at 41 months of follow-up.2 Given the
inconsistent success of adjuvant therapy, the
importance of early treatment and local surgi-
cal control cannot be overemphasized.  
Conclusions
One should keep in mind spiradenocarcino-
ma when presented with rapid morphological
changes of a long-standing cutaneous lesion in
a patient. Diagnosis must be confirmed histo-
logically, as these tumors are exceedingly rare,
and may be originally attributed to metastatic
recurrence of a metachronous cancer or other
chronic, non-healing wound. Treatment of
choice is wide surgical resection with a pro-
longed period of follow-up due to the variable
course of this disease and metastatic potential.
Staining for breast carcinoma markers, includ-
ing HER2/Neu, may reveal potential targets for
therapy. 
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